Nipro (TSE:8086) Debt-to-EBITDA : 24.99 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Nipro Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nipro's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円204,342 Mil. Nipro's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円438,489 Mil. Nipro's annualized EBITDA for the quarter that ended in Dec. 2023 was 円25,720 Mil. Nipro's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 24.99.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Nipro's Debt-to-EBITDA or its related term are showing as below:

TSE:8086' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 6.55 Med: 8.42 Max: 21.34
Current: 21.34

During the past 13 years, the highest Debt-to-EBITDA Ratio of Nipro was 21.34. The lowest was 6.55. And the median was 8.42.

TSE:8086's Debt-to-EBITDA is ranked worse than
98.61% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs TSE:8086: 21.34

Nipro Debt-to-EBITDA Historical Data

The historical data trend for Nipro's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nipro Debt-to-EBITDA Chart

Nipro Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-EBITDA

Get a 7-Day Free Trial

8.59

15.41

8.50

7.68

8.65

Nipro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															57.80	44.67	14.06	16.61	24.99

Competitive Comparison of Nipro's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, Nipro's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nipro's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nipro's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nipro's Debt-to-EBITDA falls into.

Nipro Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nipro's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(157201	+	448730)	/	70021
	=	8.65

Nipro's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(204342	+	438489)	/	25720
	=	24.99

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Nipro (TSE:8086) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Nipro Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nipro's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Nipro (TSE:8086) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nipro Corp (TSE:8086) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

5FA:Germany

Address

3-9-3 Honjo-Nishi Kita-ku, Osaka, JPN, 531-8510

Website

http://www.nipro.co.jp

Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.

Nipro (TSE:8086) Headlines

No Headlines